

Assessment of the Therapeutic Efficacy of Curcumin –Loaded Nanoparticles as a Natural Anticancer Agent

Thesis submitted to Faculty of Science Cairo
University, in partial fulfillment of the
requirements for PhD degree in Molecular
Biophysics

Submitted By

Eman Ali Eldin Ali Abdelfatah

Lecturer assistant

Biophysics Department

Faculty of Science

Cairo University

2014

APPROVAL SHEET FOR SUBMISSION

Thesis Title

Assessment of the Therapeutic Efficacy of Curcumin –Loaded Nanoparticles as a Natural Anticancer Agent

Name of candidate

Eman Ali ELDin Ali Abdelfatah

**This thesis has been approved for submission by the
supervisors**

Prof. Dr. Wafaa A. Khalil

*Professor, Biophysics Department, Faculty of Science,
Cairo University*

Dr. Nihal S. El-Bialy

*Lecturer, Biophysics Departments, Faculty of science,
Cairo University*

Prof. Dr. Wael Elshemey

*Chairman of Biophysics Department
Faculty of Science- Cairo University*



Academic Report

Student code: 1271007

Name: Eman Ali Eldin Ali

Degree Ph. D. Degree

Percent

General Grade

Specialization Molecular Biophysics

93.0%

Distinguished

Date	code	Subject Name	Mark	Points	Grade
January 2013	BP701	Computational Biophysics	90	4	Distinguished
January 2013	BP703	Molecular Biophysics	100	5	Distinguished
January 2013	BPMO732	Membrane Biophysics	90	4	Distinguished
January 2013	BP702	Biophysical Measurements	97	4.7	Distinguished
June 2012	BPMO734	Biotechnology	77	2.7	Good
June 2012	BPM715	Neurobiophysics	100	5	Distinguished
June 2012	BPMO735	Membrane Bioenergetics	90	4	Distinguished
June 2012	BPM719	Cellular Biophysics	100	5	Distinguished

Mohebat

The Dean

Munir



Table of contents

ACKNOWLEDGMENT	I
LIST OF ABBREVIATIONS	II
LIST OF FIGURES	III
ABSTRACT	IV
CHAPTER 1: INTRODUCTION	
1.1 Introduction	1
CHAPTER 2: LITERATURE REVIEW	
2.1 Cancer	6
2.2 Cancer estimated prevalence and mortality worldwide	6
2.3 Cancer treatments	7
2.4. Natural cancer therapeutics	8
2.4.1 Bioactive compounds	9
2.4.2 Polyphenols as anticancer agents	9
2.5 Curcumin	10
2.5.1 Chemistry of curcumin	10
2.5.2. Health Benefits of Curcumin	11
2.5.3 Anticancer properties of curcumin	12
2.5.4 Curcumin effects on normal cells	16

2.5.5. Curcumin safety and toxicity	17
2.6. Bioavailability of curcumin as therapeutic agent	18
2.7. Stability of curcumin	20
2. 8 Enhancement of curcumin solubility and bioavailability	23
2.8.1 Physical approaches	23
2.8.2 Soluble complexes of curcumin	23
2.8.3 Nanotechnology approaches	24
CHAPTER 3: MATERIALS & METHODS	
3.1.Materials	32
3.2.Methods: Part 1 : Gold Nanoparticles as a drug carrier for curcumin	33
3.2.1 Preparation of curcumin reduced gold nanoparticles(AuNPs-Cur)	33
3.2.2 Preparation of chitosan reduced gold nanoparticles (CSAuNps)	33
3.2.3 Characterization of the prepared nanoparticles	36
3.2.3.a Transmission electron microscopy (TEM)	36
3.2.3.b Spectroscopic measurements	36
3.2.3.c Particle size measurements by dynamic light scattering (DLS)	38
3.2.3.d Zeta potential measurements	39

3.2.3.e Stability Measurements of AuNPs-Cur	39
3.2.4 Assessment of cytotoxicity of the prepared curcumin gold- nanocarriers	39
3.2.4.a Cell culture	39
3.2.4.b Evaluation of in vitro cytotoxicity of prepared curcumin loaded NPs using MTT Assay	40
3.2.4.c Determination of cells apoptotic features by inverted microscopy	40
Part two: Polymeric nanoparticles as a drug carrier for curcumin	
3.3.1 Preparation of dextran sulphate-chitosan nanoparticles (DSCSNPs)	42
3.3.2 Preparation of Dextran Sulphate - Chitosan Nanoparticles loaded curcumin (DCSNPs-Cur)	42
3.3.3 Preparation of chitosan nanoparticles loaded curcumin (CSNPs- Cur)	43
3.3.4 Physicochemical characterization	43
3.3.5 Loading efficiency and in vitro release profile of curcumin	44
3.3.6 In vitro cytotoxicity by MTT assay	45

Part 3: Mesoporous silica nanoparticles as a drug carrier for curcumin

3.4.1 Preparation of mesoporous silica nanoparticles (MSNPs)	46
3.4.2 Preparation of mesoporous silica nanoparticles loaded by Curcumin (MSNPs-Cur)	46
3.4.3 Physicochemical characterization	47
3.4.4 Evaluation of curcumin in vitro release profile	47
3.4.5 In-vitro cytotoxicity evaluation for MSNPs-Cur	47
3.4.6 In vivo study	47
3.4.6.a Inoculation of the mice with Ehrlich ascites carcinoma cells	47
3.4.6.b In vivo therapeutic efficacy of curcumin loaded MSNPs	48
3.4.6.c Histopathological examination	49
3.4.6.d Anti-angiogenesis efficacy of MSNPs-Cur (In vivo study)	49

CHAPTER 4: RESULTS & DISCUSSION

Part one: Gold nanoparticles as a drug carrier for curcumin	51
4.1 Curcumin reduced gold nanoparticles (AuNPs-Cur)	52
4.1.1. Physicochemical characterization	52
4.1.1 (a) Morphology of AuNPs-Cur	52
4.1.1 (b) Spectroscopic measurements	54
4.1.1 (c) Particle size distribution of AuNPs-Cur	58

4.1.1 (d) Zeta potential measurements of AuNPs-Cur	58
4.1.1 (e) Stability Measurements of AuNPs-Cur	60
4.1.2 In-vitro cytotoxicity assessment of AuNPs-Cur against breast (MCF-7) and colon (HCT-116) cancer cell lines	62
4.1.2 (a) MTT cell cytotoxicity assay	62
4.1.2 (b) Apoptotic features observed by transmitted light microscope	65
4.2 Chitosan - reduced gold nanoparticles loaded by Curcumin (CSAuNPs-Cur)	67
4.2.1 Physicochemical characterization	68
4.2.1 (a) Transmission electron microscope (TEM)	68
4.2.1 (b) Fluorescence spectroscopy	70
4.2.1 (c) Fourier transform infrared spectroscopy	72
4.2.1 (d) Dynamic light scattering	75
4.2.1 (e) Zeta potential measurement	75
4.2.1 (f) Loading efficiency of the prepared CSAuNps	78
4.2.2 In-vitro cytotoxicity evaluation for CSAuNps-Cur	78
4.2.2 (a) MTT cell cytotoxicity assay	78
4.2.2 (b) Apoptotic features observed by transmitted light microscope	81

Part two: Polymeric Nanoparticles as a drug carrier for curcumin	83
4.3 Dextran sulphate-chitosan nanoparticles (DSCSNPs) loaded by curcumin (DSCSNPs-Cur)	84
4.3.1 Physicochemical characterization of DSCSNPs-Cur	84
4.3.1 (a) Transmission electron microscope	84
4.3.1 (b) Zeta potential measurement	84
4.3.1 (c) Fourier transform infrared spectroscopy	87
4.3.1 (d) Curcumin loading efficiency and in vitro release profile measurement	89
4.3.2 In vitro anticancer activity of DSCSNPs-Cur	91
4.3.2 (a) In vitro cytotoxicity by MTT assay	91
4.3.2 (b) Microscopic examination for cancer cells	93
4.4 Chitosan nanoparticles (CSNPs) loaded by curcumin (CSNPs-Cur)	95
4.4.1 Physicochemical characterization of CSNPs-Cur	95
4.4.1 (a) Transmission electron microscope (TEM)	95
4.4.1 (b) Dynamic light scattering and zeta potential measurements	97
4.4.1 (c) Fourier transform infrared spectroscopy	99
4.4.2 In vitro anticancer activity of CSNPs-Cur	101
4.4.2 (a) In vitro cytotoxicity by MTT assay	101

4.4.2 (b) Morphological examination of cancer cells using inverted microscopy	104
-------------------------------------------------------------------------------	-----

Part three: Mesoporous silica nanoparticles as a drug carrier for curcumin. 104

4.5 Mesoporous silica nanoparticles loaded with curcumin (MSNPs-Cur)	106
----------------------------------------------------------------------	-----

4.5.1 Physicochemical characterization of the prepared nanoparticles	106
----------------------------------------------------------------------	-----

4.5.1 (a) Transmission electron microscope (TEM)	106
--------------------------------------------------	-----

4.5.1 (b) Dynamic light scattering	108
------------------------------------	-----

4.5.1 (c) Zeta potential	110
---------------------------	-----

4.5.1 (d) Fourier transform infrared spectroscopy	110
---------------------------------------------------	-----

4.5.1 (e) Curcumin loading efficiency and in vitro release profile	113
--------------------------------------------------------------------	-----

4.5.2 In-vitro cytotoxicity evaluation for MSNPs-Cur	115
------------------------------------------------------	-----

4.5.2 (a) MTT cell cytotoxicity assay	115
---------------------------------------	-----

4.5.2 (b) Cancer cells morphological examination using Inverted microscopy	118
----------------------------------------------------------------------------	-----

4.5.3 In-vivo antitumor therapeutic efficacy of MSNPs-Cur	120
-----------------------------------------------------------	-----

4.5.3 (a) Tumor growth suppression	120
------------------------------------	-----

4.5.3 (b) Histopathological examination	122
-----------------------------------------	-----

4.5.4 Anti-angiogenesis efficacy of MSNPs-Cur (in vivo study)	124
---------------------------------------------------------------	-----

CHAPTER 5: CONCLUSION

129

REFERENCES

130

Acknowledgment

My deep thanks and gratitude to my advisor Prof. Dr. Wafaa A. Khalil, Biophysics Department, Faculty of Science , Cairo University, for her persistence, understanding and kindness, for her continuous support and motivation and guidance that helped me in all the time of research.

I wish to express my sincere thanks and gratitude to Dr. Nehal S. Elbially, associate professor of Biophysics, Biophysics department, faculty of Science, Cairo University, for her kind and constant guidance through all the present work, for her kind supervision and great effort in practical part in this study and writing of this thesis. I could not have imagined having a better advisor and mentor for my Ph.D study.

My deep thanks and gratitude to my colleagues Noha Mohamed and Mohamed Fathy and Mirhane Mostafa.

My deep thanks and gratitude to my mother and my husband for their infinite support throughout everything.

Finally , all my gratitude and thanks to my lovely father, my guiding light, the only person that has always looked out for my future and whose unconditional love has been my greatest strength. I can't express my gratitude and love for him in word.

List of abbreviations

AuNPs	Gold nanoparticles
AuNPs-Cur	Curcumin- reduced gold nanoparticles
cm	Centimeter
CS	Chitosan
CSAuNPs	Chitosan reduced gold nanoparticles
CSAuNPs-Cur	Curcumin loaded chitosan reduced gold nanoparticles
CSNPs	Chitosan nanoparticles
CSNPs-Cur	Curcumin loaded Chitosan nanoparticles
Cur	Curcumin
DLS	Dynamic light scattering
DS	Dextran Sulphate
DSCSNPs	Dextran Sulphate-Chitosan nanoparticles
DSCSNPs-Cur	Curcumin loaded Dextran sulphate nanoparticles
hr	hours
FTIR	Fourier transform infrared spectroscopy
i.p	Intraperitoneal
i.v	Intravenous

LE	Loading efficiency
ml	Milliliters
MSNPs	Mesoporous silica nanoparticles
MSNPs-Cur	Curcumin loaded Mesoporous silica nanoparticles
nm	Nanometer
NPs	Nanoparticles
TEM	Transmission electron microscope
ug	Microgram
TPP	Sodium tripolyphosphate

List of figures

Figure (2.1) Health benefits of curcumin.	12
Figure (2.2) Anticarcinogenic potential of curcumin.	13
Figure (2.3) Chemical structures of curcumin, its degradation products and metabolites.	22
Figure (3.1) Absorption spectra of gold nanoparticles synthesized using varying concentrations of chitosan	34
Figure (3.2) Calibration curve (different concentrations of curcumin solution versus fluorescence intensity)	37
Figure (4.1) TEM image of curcumin- reduced gold nanoparticles (AuNPs-Cur).	53
Figure (4.2) (a) UV-visible absorption spectra of free curcumin and AuNPs-Cur. (b) Fluorescence spectra of free curcumin and AuNPs-Cur.	56
Figure (4.3) FTIR Spectra of free curcumin and AuNPs-Cur.	57
Figure (4.4) Particle size distribution of AuNPs-Cur.	59
Figure (4.5) (a) Stability of AuNPs-Cur stored at 4 °C (pH 5.7) for 6 months. (b) Stability of AuNPs-Cur at (pH 7.4) for 24 hr.	61
Figure (4.6) Cytotoxicity of free curcumin and AuNPs-Cur (with different curcumin concentrations) against (a) HCT-116 cells and (b) MCF-7 cells.	64
Figure (4.7) Inverted microscope images of HCT-116 cells: (a) untreated cells, (b) treated with free curcumin and (c) treated with AuNPs-Cur . Images of MCF-7 cells: (d) untreated cells, (e) treated with free curcumin and (f) treated with AuNPs-Cur.	66

Figure (4.8) TEM images of chitosan reduced gold nanoparticles (CSAuNPs) (a) and curcumin loaded gold nanoparticles (b). 69

Figure (4.9) Fluorescence spectra of curcumin and curcumin loaded chitosan reduced gold nanoparticles (CSAuNPs-Cur). 71

Figure (4.10) FTIR spectra for Chitosan, Curcumin, Chitosan reduced gold nanoparticles (CSAuNPs) and Curcumin Loaded gold nanoparticles (CSAuNPs-Cur) 74

Figure (4.11) Particle size distribution of (a) CSAuNPs, and (b) CSAuNPs-Cur. 77

Figure (4.12) Cytotoxicity of curcumin loaded CSAuNps and free curcumin (different concentrations) against (a) HCT-116 and (b) MCF-7 cell lines. 80

Figure (4.13) Inverted microscopy images of HCT-116 cells (a) control cells, cells treated with: (b) free curcumin, (c) CSAuNPs-Cur. Microscopic observation of MCF-7 cells (e) control cells, cells treated with (f) free curcumin, (g) CSAuNPs-Cur. 82

Figure (4.14) Transmission electron microscopy images of dextran sulphate - chitosan nanoparticles (DSCSNPs) stained with uranyl acetate. 86

Figure (4.15) FTIR spectrum of dextran sulphate, chitosan, curcumin, dextran sulphate–chitosan NPs (DSCSNPs), and curcumin loaded dextran sulphate–chitosan NPs (DSCSNPs-Cur). 88

Figure (4.16) Drug release profile of DSCSNPs-Cur at pH 7.4 and 5.5 over a time period of one week. 90

- Figure (4.17)** Cytotoxicity of DSCSNPs-Cur and free curcumin against (a) HCT-116 and (b) MCF-7 cancer cell lines, 24 hr post incubation. 92
- Figure (4.18)** Inverted microscopy images of control HCT-116 cells (a), HCT-116 cells incubated with free curcumin (b), HCT-116 cells incubated with DSCSNPs-Cur (c), control MCF-7 cells (d), MCF-7 cells incubated with free curcumin (e) and (f) MCF-7 cells incubated with DSCSNPs-Cur. 94
- Figure (4.19 a & b).** Transmission electron microscopy images of chitosan nanoparticles (CSNPs) (stained with uranyl acetate). 96
- Figure (4.20)** Particle size distribution of (a) CSNPs, and (b) CSNPs-Cur. 98
- Figure (4.21)** FTIR spectra for chitosan, curcumin, TPP and curcumin loaded chitosan nanoparticles (CSNPs-Cur). 100
- Figure (4.22)** Cytotoxicity of curcumin loaded CSNPs (CSNPs-Cur) and free curcumin (different concentrations) against (a) HCT-116 and (b) MCF-7 cell lines. 103
- Figure (4.23)** Inverted microscopy images of control HCT-116 cells (a), HCT-116 cells incubated with free curcumin (b), HCT-116 cells incubated with CSNPs-Cur (c), control MCF-7 cells (d), MCF-7 cells treated with free curcumin (e) and MCF-7 cells treated with CSNPs-Cur (f). 105
- Figure (4.24)** TEM image of mesoporous silica nanoparticles (MSNPs) 107
- Figure (4.25)** Particle size distribution of MSNPs. 109
- Figure (4.26)** FTIR spectra for: free curcumin, mesoporous silica nanoparticles (MSNPs) and curcumin-loaded mesoporous silica nanoparticles (MSNPs-Cur). 112

Figure (4.27) Drug release profile of MSNPs-Cur at: pH 7.4 simulating normal blood/tissues and pH 5.5 simulating tumor micro-environment. 114

Figure (4.28) Cytotoxicity of free curcumin and MSNPs-Cur against HCT-116 (a) and MCF-7 cell lines (b). 117

Figure (4.29) Inverted microscopy images of control HCT-116 cells (a), HCT-116 cells incubated with free curcumin (b), HCT-116 cells incubated with MSNPs-Cur (c) and control MCF-7 cells (d), MCF-7 cells incubated with free curcumin (e), and MCF-7 cells incubated with MSNPs-Cur (f). 119

Figure (4.30) Average change in tumor volume for mice of control group, MSNPs-Cur treated group B and free curcumin treated group C. 121

Figure (4.31) Histopathology of Ehrlich tumor sections stained with H&E for (a) control group A and (b) MSNPs-Cur treated group B 150x. 123

Figure (4.32). (a) photographic image of the collected ascites fluid 13 days post treatment. (b) Ehrlich ascites tumor volume for untreated mice group 1, free curcumin and MSNPs-Cur treated mice group 2 &3 respectively (n=5).

127

Figure (4.33) Peritoneal lining from Ehrlich ascites tumor bearing mice for: (a) untreated control group, (b) mice group treated with free curcumin and (c) mice group treated with MSNPs-Cur. 128

ABSTRACT

Cancer is a lethal disease caused by damage in the genetic material (i.e. DNA) which leads to uncontrollable cell division. Chemotherapy is one of the three main methods of cancer treatment including surgical interference and radiotherapy. Chemotherapy is characterized with its applicability to all types and stages of cancer. The major problem associated with chemotherapy is the inability to deliver pharmaceuticals to a specific site of the body without inducing normal tissue toxicity. As a consequence, the development of an alternative modalities using ‘Natural anticancer agents’ open up new avenue for future cancer therapy due to their safety. Curcumin is one of the most promising natural anticancer agents, however, its medical application has been limited by its poor water solubility and bioavailability. Attempts have been made to encapsulate curcumin in different carriers, but the interest in nanocarriers for cancer chemotherapy is growing to develop a biodegradable controlled drug delivery vehicles that improve the bioavailability and solubility of curcumin.

The current study, focused on designing a biocompatible delivery systems to be used as nanocarriers of the natural anti-cancer curcumin allowing their applications either *in vitro* or *in vivo*. Therefore, five nanoparticles with different based fabrications were prepared as a nanocarrier for curcumin. These nanoparticles fall under three categories of nanoparticulate delivery systems including: gold nanoparticles, polymeric nanocarriers and inorganic nanocarriers (mesoporous silica). The physicochemical properties of the prepared nanocarriers were investigated using different techniques. Transmission electron microscopy (TEM) which revealed the spherical smooth surface of all nano-formulations. Dynamic light scattering (DLS) for measuring the hydrodynamic sizes of all the nanocarriers. The stability of the

five nano-formulations was also studied by zeta potential measurements indicating their high stability. The optical properties of the prepared NPs were investigated using UV-VIS and fluorescence spectroscopy. Fourier transform infrared spectroscopy (FTIR) assessment revealed that curcumin was successfully loaded on or in the nanocarriers. *In vitro* studies elucidated that curcumin loaded nanoparticles have more potent therapeutic effect than free curcumin against both HCT-116 and MCF-7 cancer cells. *In vivo* studies for a selective curcumin loaded nanocarriers proved that such nanoparticles can provide a high therapeutic efficacy represented by the inhibition in tumor growth. Furthermore, curcumin loaded mesoporous silica NPs (MSNPs-Cur) revealed higher anti-angiogenesis potential compared with that for free curcumin. Therefore, curcumin-loaded nanoparticles provide an opportunity to expand the clinical repertoire of this efficacious agent by enabling ready aqueous dispersions.